Findings

What do systematic reviews say?

8 questions · 16 findings · 1 reviews · Developmental, Psychosocial and Learning Problems

No studies found 0 · 0%GRADE not reported 8 · 50%Very low 2 · 12.5%Low 6 · 37.5%Moderate 0 · 0%High 0 · 0%

Inattention Measured using SNAP‐IV inattention subscale (range 0 to 27) · Children aged 6 to 18 years with ASD

2 findings from 1 review

Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 51 participants
Low
Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 71 participants
Low

Impulsivity · Children aged 6 to 18 years with ASD

2 findings from 1 review

Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 48 participants
GRADE not reported
Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
GRADE not reported

Hyperactivity · Children aged 6 to 18 years with ASD

2 findings from 1 review

Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 71 participants
Low
Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 73 participants
Low

Impaired social interaction · Children aged 6 to 18 years with ASD

2 findings from 1 review

Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 71 participants
Very low
Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 63 participants
Very low

Impaired communication · Children aged 6 to 18 years with ASD

2 findings from 1 review

Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 48 participants
GRADE not reported
Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
GRADE not reported

Stereotypical behaviours · Children aged 6 to 18 years with ASD

2 findings from 1 review

Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 48 participants
GRADE not reported
Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 69 participants
Low

Overall ASD · Children aged 6 to 18 years with ASD

2 findings from 1 review

Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 48 participants
GRADE not reported
Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 36 participants
Low

Total number of adverse events · Children aged 6 to 18 years with ASD

2 findings from 1 review

Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 108 participants
GRADE not reported
Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 79 participants
GRADE not reported